Lysostaphin (5 mg/kg, intravenous injection, once daily for 3 consecutive days) effectively clears systemic Staphylococcus aureus (MSSA) infections in CF-1 mice[2].
Lysostaphin (50 mg/kg, intravenous injection, single dose) effectively clears Staphylococcus aureus (MSSA and MRSA) infections from the kidneys, spleen, and liver, but is not superior to repeated lower doses[2].
Lysostaphin (1 mg/kg, intravenous injection, once daily for 3 consecutive days) combined with Oxacillin (HY-B0925A) achieves the same antibacterial effect with a lower concentration of Lysostaphin. When combined with Vancomycin, low-dose Lysostaphin (1 mg/kg) similarly shows enhanced efficacy against MRSA[2].
| Animal Model: | Systemic infection model in CF-1 mice induced by methicillin-susceptible Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA)[2] |
| Dosage: | 1, 5, 25, 50 mg/kg |
| Administration: | Intravenous injection (i.v.), single high-dose administration: 25 mg/kg or 50 mg/kg intravenous injection, single dose; Once daily administration: 1 or 5 mg/kg, once daily for 3 days. |
| Result: | Cleared MSSA from the blood and organs of mice (5 mg/kg for 3 days).
Cleared MSSA and MRSA from the kidneys, spleen, and liver (A higher single dose of 50 mg/kg).
Improved effectiveness and allowed reduction of the lysostaphin dose to 1 mg/kg for MRSA infections (Combined with Oxacillin (HY-B0925A) or Vancomycin (HY-B0671)). |
